SGC-CBP30, a potent inhibitor of the highly selective CBP/p300 bromodomain, has shown therapeutic potential in a variety of diseases, including cancers, gastrointestinal syndromes, sepsis, and organ fibrosis62,71–73. The gene discussed is EP300; the disease is cancer.